|Podcasts|July 10, 2018

Episode 12: Midwest Biotechs and Regenerative Medicine

Gil Van Bokkelen, CEO and co-founder of Athersys, talks about a pivotal moment during medical school that led him and his co-founders to eventually launch Athersys, the decision to start the company in Ohio instead of his native Northern California, and the secret to staying resilient in the c-suite, even when facing extraordinary challenges.

Gil Van Bokkelen, CEO and co-founder of Athersys, talks about a pivotal moment during medical school that led him and his co-founders to eventually launch Athersys, the decision to start the company in Ohio instead of his native Northern California, and the secret to staying resilient in the c-suite, even when facing extraordinary challenges.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 


Related to this article

Pharmaceutical executive daily
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.